Loading...
•
Mar 31, 2020
Viking Therapeutics Q1 2020 Earnings Report
Reported first quarter 2020 financial results and provided a corporate update.
Key Takeaways
Viking Therapeutics reported a net loss of $9.7 million, or $0.13 per share, for the first quarter ended March 31, 2020. The company ended the quarter with $269.2 million in cash, cash equivalents and short-term investments.
Enrollment continues in Phase 2b VOYAGE study of VK2809 in NASH.
New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL.
IND Filing for VK0214 in X-ALD on Track for Mid-Year.
Balance sheet remains strong, Quarter-End Cash Approximately $270 Million.
Forward Guidance
Viking anticipates completion of enrollment in VOYAGE in the first half of 2021. The company currently expects to submit an IND for VK0214 this summer and initiate clinical studies with this candidate in the third quarter.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...